Indian Hotels Company, PVR Inox and Zydus Lifesciences from the BSE 500 index have hit their respective 52-week highs.
Analysts at Jefferies remain positive on Emcure Pharma's near- to mid-term outlook, supported by multiple growth drivers and operating-leverage benefits.
Emcure Pharmaceuticals reports 24.2 per cent revenue growth in Q2FY27, led by strong international sales, while domestic business expands 12 per cent and net profit rises 33.7 per cent
Emcure Pharmaceuticals will merge its wholly owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, with itself under the proposed scheme.
Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving
Motilal Oswal Wealth Management Research Desk recommends 2 stocks each from the large-cap, mid-cap and small-cap segment for August 2026.
The approval makes the innovator molecule from Novo Nordisk the first and only GLP-1 receptor agonist approved in India for the treatment of the disease.
The drugmaker will market Poviztra for treating MASH after CDSCO approved the new indication for innovator semaglutide, expanding the medicine's approved uses in India
Restructuring positions biotech arm to focus on biologics and biosimilar